The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Ever been told that your blood pressure numbers are creeping up? High blood pressure (hypertension) can increase the risk of ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

Patients' ankle brachial index, a measure of blood flow ... Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...